Silence Therapeutics (SLN) Cash from Investing Activities (2024 - 2026)

Silence Therapeutics (SLN) has 3 years of Cash from Investing Activities data on file, last reported at $10.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 122.53% year-over-year to $10.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (up 138.86% YoY), and the FY2025 full-year result was -$48.0 million, down 118.48% from the prior year.
• Cash from Investing Activities advanced to $10.0 million in Q1 2026, from -$53.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $66.1 million in Q4 2024 to a low of -$53.3 million in Q4 2025.
• A 3-year average of -$6.7 million and a median of -$1.6 million in 2025 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 234.48% in 2025, while the deepest fall reached 3532.56% in 2025.
• Tracing SLN's Cash from Investing Activities over 3 years: stood at $66.1 million in 2024, then sank by 180.66% to -$53.3 million in 2025, then surged by 118.75% to $10.0 million in 2026.
• Business Quant data shows SLN's Cash from Investing Activities at $10.0 million in Q1 2026, -$53.3 million in Q4 2025, and $51.3 million in Q3 2025.